Literature DB >> 17216419

Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.

Jessica J Hawes1, Robert G Tuskan, Karlyne M Reilly.   

Abstract

Neurofibromatosis type 1 (NF1) is the most common cancer predisposition syndrome affecting the nervous system, with elevated risk for both astrocytoma and peripheral nerve sheath tumors. NF1 is caused by a germline mutation in the NF1 gene, with tumors showing loss of the wild type copy of NF1. In addition, NF1 heterozygosity in surrounding stroma is important for tumor formation, suggesting an additional role of haploinsufficiency for NF1. Studies in mouse models and NF1 families have implicated modifier genes unlinked to NF1 in the severity of the disease and in susceptibility to astrocytoma and peripheral nerve sheath tumors. To determine if differences in Nf1 expression may contribute to the strain-specific effects on tumor predisposition, we examined the levels of Nf1 gene expression in mouse strains with differences in tumor susceptibility using quantitative polymerase chain reaction. The data presented in this paper demonstrate that strain background has as much effect on Nf1 expression levels as mutation of one Nf1 allele, indicating that studies of haploinsufficiency must be carefully interpreted with respect to strain background. Because expression levels do not correlate entirely with the susceptibility or resistance to tumors observed in the strain, these data suggest that either variation in Nf1 levels is not responsible for the differences in astrocytoma and peripheral nerve sheath tumor susceptibility in Nf1-/+;Trp53-/+cis mice, or that certain mouse strains have evolved compensatory mechanisms for differences in Nf1 expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216419      PMCID: PMC6687394          DOI: 10.1007/s10048-006-0078-5

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  32 in total

1.  Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes.

Authors:  D H Gutmann; Y L Wu; N M Hedrick; Y Zhu; A Guha; L F Parada
Journal:  Hum Mol Genet       Date:  2001-12-15       Impact factor: 6.150

Review 2.  Clinical manifestations and management of neurofibromatosis type 1.

Authors:  James H Tonsgard
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

3.  Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.

Authors:  Yuan Zhu; Takayuki Harada; Li Liu; Mark E Lush; Frantz Guignard; Chikako Harada; Dennis K Burns; M Livia Bajenaru; David H Gutmann; Luis F Parada
Journal:  Development       Date:  2005-12       Impact factor: 6.868

4.  Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo.

Authors:  Biplab Dasgupta; David H Gutmann
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.167

5.  Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.

Authors:  Karlyne M Reilly; Robert G Tuskan; Emily Christy; Dagan A Loisel; Jeremy Ledger; Roderick T Bronson; C Dahlem Smith; Shirley Tsang; David J Munroe; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-19       Impact factor: 11.205

6.  Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene.

Authors:  R T Geist; D H Gutmann
Journal:  Neurosci Lett       Date:  1996-06-21       Impact factor: 3.046

7.  Alternative splicing of exons 29 and 30 in the neurofibromatosis type 1 gene.

Authors:  V M Park; K A Kenwright; D B Sturtevant; E K Pivnick
Journal:  Hum Genet       Date:  1998-10       Impact factor: 4.132

8.  Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormone.

Authors:  X Yu; J Milas; N Watanabe; N Rao; S Murthy; O L Potter; M J Wenning; W D Clapp; J M Hock
Journal:  Calcif Tissue Int       Date:  2006-03-08       Impact factor: 4.333

9.  GalR1, but not GalR2 or GalR3, levels are regulated by galanin signaling in the locus coeruleus through a cyclic AMP-dependent mechanism.

Authors:  Jessica J Hawes; Darlene H Brunzell; David Wynick; Venetia Zachariou; Marina R Picciotto
Journal:  J Neurochem       Date:  2005-06       Impact factor: 5.372

10.  Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo.

Authors:  D A Ingram; F C Yang; J B Travers; M J Wenning; K Hiatt; S New; A Hood; K Shannon; D A Williams; D W Clapp
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

View more
  21 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

Review 3.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

Review 4.  The genomic revolution and endocrine pathology.

Authors:  Suzana S Couto; Robert D Cardiff
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 5.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

6.  Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk.

Authors:  Karlyne M Reilly
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

7.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Authors:  Stephen M Wiesner; Stacy A Decker; Jon D Larson; Katya Ericson; Colleen Forster; Jose L Gallardo; Chunmei Long; Zachary L Demorest; Edward A Zamora; Walter C Low; Karen SantaCruz; David A Largaespada; John R Ohlfest
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency.

Authors:  Alexander Pemov; Caroline Park; Karlyne M Reilly; Douglas R Stewart
Journal:  BMC Genomics       Date:  2010-03-22       Impact factor: 3.969

Review 9.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

10.  Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis.

Authors:  Stephanie N Brosius; Amy N Turk; Stephanie J Byer; Nicole M Brossier; Latika Kohli; Amber Whitmire; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Acta Neuropathol       Date:  2014-04       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.